The stromelysin-1 (MMP-3) gene and risk of coronary artery disease: a candidate gene that has won the election?

• References

• 1 Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-72.
• 2 Liu P-Y, Chen J-H, Li Y-H, Wu H-L, Shi G-Y. Synergistic effect of stromelysin-1 (matrix metalloproteinnase-3) promoter 5A/6A poly-morphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003; 89: 132-9.
• 3 Ye S, Humphries S, Henney A. Matrix metal-loproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci 1998; 94: 103-10.
• 4 Henney AM, Wakeley PR, Davies MJ. et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8.
• 5 Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-15.
• 6 Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055-60.
• 7 Ye S, Whatling C, Watkins H, Henney A. Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett 1999; 450: 268-72.
• 8 Humphries SE, Luong LA, Talmud PJ. et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gem-fibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 1998; 139: 49-56.
• 9 de Maat MP, Jukema JW, Ye S. et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83: 852-6.
• 10 Terashima M, Akita H, Kanazawa K. et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 179
• 11 Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001; 358: 115-9.
• 12 Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 –174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243-52.
• 13 Li R, Boerwinkle E, Olshan AF. et al. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 2000; 149: 451-62.
• 14 Bergmann S, Siekmeier R, Mix C, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol 1998; 114: 269-75.
• 15 Schonbeck U, Mach F, Sukhova GK. et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo . J Exp Med 1999; 189: 843-53.
• 16 Carty CS, Soloway PD, Kayastha S. et al. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg 1966; 24: 927-34.
• 17 Inoue I, Goto S, Mizotani K. et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR-α) in primary endothelial cells. Life Sci 2000; 67: 863-76.
• 18 Humphries SE, Martin S, Cooper J, Miller GJ. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter poly-morphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66: 343-52.
• 19 Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001; 21: 1440-5.
• 20 McBride CM, Bepler G, Lipkus IM. et al. Incorporating genetic susceptibility feedback into a smoking cessation program for Afri-can-American smokers with low income. Cancer Epidemiol Biomarkers Prev 2002; 11: 521-8.